83 related articles for article (PubMed ID: 27992692)
1. Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased?
Hellgren K; Baecklund E; Backlin C; Sundstrom C; Smedby KE; Askling J
Arthritis Rheumatol; 2017 Apr; 69(4):700-708. PubMed ID: 27992692
[TBL] [Abstract][Full Text] [Related]
2. Rheumatoid arthritis and lymphoma: Incidence, pathogenesis, biology, and outcome.
Klein A; Polliack A; Gafter-Gvili A
Hematol Oncol; 2018 Dec; 36(5):733-739. PubMed ID: 29862535
[TBL] [Abstract][Full Text] [Related]
3. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
4. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis.
Tarp S; Eric Furst D; Boers M; Luta G; Bliddal H; Tarp U; Heller Asmussen K; Brock B; Dossing A; Schjødt Jørgensen T; Thirstrup S; Christensen R
Rheumatology (Oxford); 2017 Mar; 56(3):417-425. PubMed ID: 28013201
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib in the treatment of active rheumatoid arthritis in adults.
Fleischmann R
Immunotherapy; 2018 Jan; 10(1):39-56. PubMed ID: 29043892
[TBL] [Abstract][Full Text] [Related]
6. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.
Moots RJ; Sebba A; Rigby W; Ostor A; Porter-Brown B; Donaldson F; Dimonaco S; Rubbert-Roth A; van Vollenhoven R; Genovese MC
Rheumatology (Oxford); 2017 Apr; 56(4):541-549. PubMed ID: 28013198
[TBL] [Abstract][Full Text] [Related]
7. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.
Simon TA; Boers M; Hochberg M; Baker N; Skovron ML; Ray N; Singhal S; Suissa S; Gomez-Caminero A
Arthritis Res Ther; 2019 Nov; 21(1):228. PubMed ID: 31703717
[TBL] [Abstract][Full Text] [Related]
8. Risk of malignant lymphoma in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs and methotrexate
.
Inose R; Hosomi K; Takahashi K; Yokoyama S; Takada M
Int J Clin Pharmacol Ther; 2019 Feb; 57(2):63-72. PubMed ID: 30526810
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.
Harada T; Iwasaki H; Muta T; Urata S; Sakamoto A; Kohno K; Takase K; Miyamura T; Sawabe T; Asaoku H; Oryoji K; Fujisaki T; Mori Y; Yoshimoto G; Ayano M; Mitoma H; Miyamoto T; Niiro H; Yamamoto H; Oshiro Y; Miyoshi H; Ohshima K; Takeshita M; Akashi K; Kato K
Br J Haematol; 2021 Jul; 194(1):101-110. PubMed ID: 33822354
[TBL] [Abstract][Full Text] [Related]
10. Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis: Results from a Japanese multi-institutional retrospective study.
Honda S; Sakai R; Inoue E; Majima M; Konda N; Takada H; Kihara M; Yajima N; Nanki T; Yamamoto K; Takeuchi T; Harigai M
Mod Rheumatol; 2022 Jan; 32(1):16-23. PubMed ID: 33428479
[TBL] [Abstract][Full Text] [Related]
11. Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients.
Saito S; Takeuchi T
J Clin Exp Hematop; 2019; 59(4):145-155. PubMed ID: 31866617
[TBL] [Abstract][Full Text] [Related]
12. A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy.
Xie W; Xiao S; Huang Y; Sun X; Gao D; Ji L; Li G; Zhang Z
Rheumatology (Oxford); 2020 May; 59(5):930-939. PubMed ID: 31620795
[TBL] [Abstract][Full Text] [Related]
13. Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management.
De Cock D; Hyrich K
Best Pract Res Clin Rheumatol; 2018 Dec; 32(6):869-886. PubMed ID: 31427060
[TBL] [Abstract][Full Text] [Related]
14. [Methotrexate-associated lymphoproliferative disorder].
Kaneko Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(3):174-178. PubMed ID: 28747604
[TBL] [Abstract][Full Text] [Related]
15. Risk of cancer in patients with psoriasis on biological therapies: a systematic review.
Peleva E; Exton LS; Kelley K; Kleyn CE; Mason KJ; Smith CH
Br J Dermatol; 2018 Jan; 178(1):103-113. PubMed ID: 28722163
[TBL] [Abstract][Full Text] [Related]
16. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
Hellgren K; Di Giuseppe D; Smedby KE; Sundström C; Askling J; Baecklund E;
Rheumatology (Oxford); 2021 Feb; 60(2):809-819. PubMed ID: 32810256
[TBL] [Abstract][Full Text] [Related]
17. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.
Sepriano A; Kerschbaumer A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JW; Burmester GR; de Wit M; Falzon L; Landewé R
Ann Rheum Dis; 2020 Jun; 79(6):760-770. PubMed ID: 32033941
[TBL] [Abstract][Full Text] [Related]
18. Allergic disease, corticosteroid use, and risk of Hodgkin lymphoma: A United Kingdom nationwide case-control study.
Rafiq M; Hayward A; Warren-Gash C; Denaxas S; Gonzalez-Izquierdo A; Lyratzopoulos G; Thomas S
J Allergy Clin Immunol; 2020 Mar; 145(3):868-876. PubMed ID: 31730878
[TBL] [Abstract][Full Text] [Related]
19. Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.
Din L; Sheikh M; Kosaraju N; Smedby KE; Bernatsky S; Berndt SI; Skibola CF; Nieters A; Wang S; McKay JD; Cocco P; Maynadié M; Foretová L; Staines A; Mack TM; de Sanjosé S; Vyse TJ; Padyukov L; Monnereau A; Arslan AA; Moore A; Brooks-Wilson AR; Novak AJ; Glimelius B; Birmann BM; Link BK; Stewart C; Vajdic CM; Haioun C; Magnani C; Conti DV; Cox DG; Casabonne D; Albanes D; Kane E; Roman E; Muzi G; Salles G; Giles GG; Adami HO; Ghesquières H; De Vivo I; Clavel J; Cerhan JR; Spinelli JJ; Hofmann J; Vijai J; Curtin K; Costenbader KH; Onel K; Offit K; Teras LR; Morton L; Conde L; Miligi L; Melbye M; Ennas MG; Liebow M; Purdue MP; Glenn M; Southey MC; Din M; Rothman N; Camp NJ; Wong Doo N; Becker N; Pradhan N; Bracci PM; Boffetta P; Vineis P; Brennan P; Kraft P; Lan Q; Severson RK; Vermeulen RCH; Milne RL; Kaaks R; Travis RC; Weinstein SJ; Chanock SJ; Ansell SM; Slager SL; Zheng T; Zhang Y; Benavente Y; Taub Z; Madireddy L; Gourraud PA; Oksenberg JR; Cozen W; Hjalgrim H; Khankhanian P
Genet Epidemiol; 2019 Oct; 43(7):844-863. PubMed ID: 31407831
[TBL] [Abstract][Full Text] [Related]
20. Systemic lupus erythematosus and lymphoma: Incidence, pathogenesis and biology.
Klein A; Polliack A; Gafter-Gvili A
Leuk Res; 2018 Dec; 75():45-49. PubMed ID: 30458319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
